Renaissance Technologies LLC grew its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) by 581.6% during the 2nd quarter, Holdings Channel reports. The firm owned 503,293 shares of the biopharmaceutical company’s stock after buying an additional 429,456 shares during the period. Renaissance Technologies LLC’s holdings in Abeona Therapeutics were worth $2,134,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in ABEO. Acadian Asset Management LLC acquired a new position in shares of Abeona Therapeutics during the 1st quarter worth approximately $91,000. Bank of New York Mellon Corp lifted its position in shares of Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 2,434 shares during the last quarter. Rosalind Advisors Inc. bought a new stake in shares of Abeona Therapeutics during the 2nd quarter worth $7,420,000. Finally, Western Standard LLC lifted its position in shares of Abeona Therapeutics by 68.5% during the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock worth $9,871,000 after buying an additional 553,377 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.
Abeona Therapeutics Stock Down 3.6 %
ABEO stock opened at $6.23 on Thursday. Abeona Therapeutics Inc has a twelve month low of $3.05 and a twelve month high of $9.01. The company has a quick ratio of 7.48, a current ratio of 7.48 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average is $5.34 and its 200-day moving average is $5.31. The firm has a market capitalization of $255.20 million, a PE ratio of -1.95 and a beta of 1.53.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, August 14th. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research note on Friday, September 20th.
Get Our Latest Analysis on ABEO
Abeona Therapeutics Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Articles
- Five stocks we like better than Abeona Therapeutics
- How to Calculate Stock Profit
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- The Most Important Warren Buffett Stock for Investors: His Own
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.